Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data (SKMEL2) after treatment with MAPKi, HDACi or both

ABSTRACT: Expression data (SKMEL2) after treatment with MAPKi, HDACi or both

PROVIDER: PRJNA516831 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data (A2058) after treatment with MAPKi, HDACi or both

Project description:Expression data (A2058) after treatment with MAPKi, HDACi or both

| PRJNA516830 | ENA

Expression data (Hs695T) after treatment with MAPKi, HDACi or both

Project description:Expression data (Hs695T) after treatment with MAPKi, HDACi or both

| PRJNA516828 | ENA

Expression data (SKMEL2) after treatment with MAPKi, HDACi or both

Project description:Transcriptional profiles were examined in SKMEL2 melanoma cells treated with vehicle (DMSO), dabrafenib+trametinib (DT, MAPKi), entinostat (E, HDACi) or all 3 agents (DTE) at 24 hours, prior to the commencement of cell death, to investigate the molecular mechamism by which these drugs and their combinations are functioning.

2019-01-25 | GSE125563 | GEO

Expression data (Hs695T) after treatment with MAPKi, HDACi or both

Project description:Transcriptional profiles were examined in Hs695T melanoma cells treated with vehicle (DMSO), dabrafenib+trametinib (DT, MAPKi), entinostat (E, HDACi) or all 3 agents (DTE) at 24 hours, prior to the commencement of cell death, to investigate the molecular mechamism by which these drugs and their combinations are functioning.

2019-01-25 | GSE125562 | GEO

Expression data (A2058) after treatment with MAPKi, HDACi or both

Project description:Transcriptional profiles were examined in A2058 melanoma cells treated with vehicle (DMSO), dabrafenib+trametinib (DT, MAPKi), entinostat (E, HDACi) or all 3 agents (DTE) at 24 hours, prior to the commencement of cell death, to investigate the molecular mechamism by which these drugs and their combinations are functioning.

2019-01-25 | GSE125560 | GEO

Expression data of 3 melanoma cell lines after treatment with MAPKi, HDACi or both

Project description:Expression data of 3 melanoma cell lines after treatment with MAPKi, HDACi or both

| PRJNA516822 | ENA

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment

Project description:Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment

| PRJNA303171 | ENA

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment (Affymetrix)

Project description:Treatment of advanced V600BRAF mutant melanoma using a BRAF inhibitor (BRAFi) or its combination with a MEKi typically elicits partial responses. We compared the transcriptomes of patient-derived tumors regressing on MAPKi therapy against MAPKi-induced temporal transcriptomic states in human melanoma cell lines or murine melanoma in immune-competent mice. Despite heterogeneous dynamics of clinical tumor regression, residual tumors displayed highly recurrent transcriptomic alterations and enriched processes, which were also observed in MAPKi-selected cell lines (implying tumor cell-intrinsic reprogramming) or in bulk mouse tumors (and the CD45-negative or -positive fractions,, implying tumor cell-intrinsic or stromal/immune alterations, respectively). Tumor cell-intrinsic reprogramming attenuated MAPK-dependency, while enhancing mesenchymal, angiogenic and IFN-inflammatory features and growth/survival dependence on multi-RTKs and PD-L2. In the immune compartment, PD-L2 upregulation in CD11c+ immunocytes drove the loss of T-cell inflammation and promoted BRAFi resistance. Thus, residual melanoma early on MAPKi therapy already displays potentially exploitable adaptive transcriptomic, epigenomic, immune-regulomic alterations.

2017-09-05 | GSE75311 | GEO

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment [Y1.7.FPKM.batch1.2]

2017-09-13 | GSE103725 | GEO

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment (RNA-seq_Patient.batch3)

2017-09-08 | GSE103658 | GEO